BCRX vs EXEL
BioCryst Pharmaceuticals, Inc. vs Exelixis — AI-powered side-by-side comparison
BCRX
BioCryst Pharmaceuticals, Inc.
55
Watch
VS
| Metric | BCRX | EXEL |
|---|
| AI Score |
55
|
67
|
| Price |
$10.35
|
$51.30
|
| P/E Ratio |
-7.19×
|
15.60×
|
| ROE |
-221.4%
|
36.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
23.5%
|
96.5%
|
| Debt / Equity |
-0.90×
|
0.09×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
75.0
|
41.0
|
| Beta |
0.554
|
0.422
|
| Expected Upside |
—
|
+8.7%
|
AI Committee View
Current Innellis committee reasoning for BCRX versus EXEL.
EXEL leads by 12 points.
EXEL scores 67/100 (Buy) versus BCRX at 55/100 (Watch).
BCRX Committee View
33% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 68.7% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 2.09) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 68.7% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 13.9x prices in significant intangible value — Value
- ROE of only -328.8% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.09 adds balance-sheet risk to the value case — Value
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical